MAY 30, 2014 03:00 PM PDT

Opportunities to simplify clinical lipid assessment

Speakers
  • Clinical Associate Professor, Dept of Biochemistry, Royal Prince Alfred Hospital
    Biography
      David Sullivan is a physician and chemical pathologist in the Department of Clinical Biochemistry at Royal Prince Alfred Hospital.  This includes conjoint appointment as Clinical Associate Professor, Central Clinical School, Faculty of Medicine and Charles Perkins Centre, University of Sydney. David has a long-term interest in lipid metabolism with particular emphasis on the gene environment interactions contributing to cardiovascular disease. He has been involved in the early use of many forms of lipid-lowering intervention. He remains a national leader of efforts to improve the detection and management of severe inherited dyslipidaemia, such as that seen in Familial Hypercholesterolaemia. David has experience in several international clinical posts, including World Health Organization (WHO) Fellowship at the MRC Lipoprotein Unit, Royal Postgraduate School of Medicine, Hammersmith Hospital, London and co-ordination of international clinical studies from the WHO reference lipid laboratory in Wageningen, Netherlands. In addition to his clinical activities in Australia, he has served on numerous clinical committees including the management committees of the LIPID and FIELD trials. Current research interests are focussed on biomarkers, post-prandial metabolism and novel therapies.

    Abstract:

    Laboratory assessment of serum lipid and lipoprotein levels is essential for the management of the risk of atherothrombotic cardiovascular disease (CVD). Traditionally, this has involved the measurement of fasting levels of total and HDL cholesterol, as well as calculation or direct measurement of LDL cholesterol (LDL-C). Contemporaneous fasting triglyceride levels are required for calculation of LDL-C.

    Several recent developments have created uncertainty concerning the current and future use of LDL-C as the main focus of CVD management. This presentation will examine the clinical and therapeutic insights that have prompted a reduction in the emphasis on LDL-C. It will also explore alternatives that may enhance laboratory CVD risk assessment, some of which are relatively simple.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    Loading Comments...
    Show Resources